Tiotropium
As of the edition of 20 October 2026, Tiotropium is a small molecule: marketed, first approved in 2002 (CA); acts on CHRM3.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2010
- Kind
- Small molecule
- Brand name
- Spiriva
- First approved
- 20 November 2002 (CA)
- Approvals on record
- 16 in 5 regions
- Holder of the most recent approval
- Boehringer Ingelheim; 2 holders in all
- Registered trials
- 251, 12 stopped early
- Disease areas
- Lungs and airways; Immune system; Infections; Digestive system; Inherited and neonatal; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CHRM3 | Muscarinic acetylcholine receptor M3 | P20309 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 43 | 37 | 0 | 2 |
| Phase 1 | 30 | 28 | 0 | 0 |
| Phase 2 | 34 | 31 | 0 | 2 |
| Phase 3 | 82 | 78 | 0 | 2 |
| Phase 4 | 62 | 51 | 2 | 6 |
| All trials | 251 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Boehringer Ingelheim | Applicant and Lead sponsor of trials | 1998 to now |